PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Medical, Oral and Biotechnological Sciences, \'G. D\'Annunzio\' University, Chieti, Italy; VCU Pauley Heart Center, Virginia Commonwealth University, Richmond VA, USA.\', \'Department of Medicine and Ageing Sciences, \'G. D\'Annunzio\' University, Chieti-Pescara, Italy; Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands.\', \'Department of Medical, Oral and Biotechnological Sciences, \'G. D\'Annunzio\' University, Chieti, Italy.\', \'Unit of Clinical Pathology, Pescara General Hospital, Pescara, Italy.\', \'Infectious Diseases Unit, Pescara General Hospital, Pescara, Italy.\', \'Respiratory Medicine Unit, Pescara General Hospital, Pescara, Italy.\', \'Hospital Pharmacy, Pescara General Hospital, Pescara, Italy.\', \'VCU Pauley Heart Center, Virginia Commonwealth University, Richmond VA, USA.\', \'Infectious Diseases Unit, Pescara General Hospital, Pescara, Italy. Electronic address: parrutig@gmail.com.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • S1201-9712(20)30616-010.1016/j.ijid.2020.07.078
?:hasPublicationType
?:journal
  • International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
is ?:pmid of
?:pmid
?:pmid
  • 32768701
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Low-dose subcutaneous tocilizumab to prevent disease progression in patients with moderate COVID-19 pneumonia and hyperinflammation.
?:type
?:year
  • 2020

Metadata

Anon_0  
expand all